Answers are grounded in this paper and cite their sources.
Phase I/II study shows activity of olaparib and irinotecan in pediatric tumors, suggesting potential treatments for young patients.
Olaparib combined with irinotecan demonstrated activity in pediatric tumors which was enriched among tumors that exhibited aneuploidy.
No takes yet. Share an insight, caveat, or question.
Gatz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: